Solid pharmaceutical compositions comprising biopterin derivatives and uses of suchcompositions
The present invention relates to a method of treating a disease in a subject, comprising administering to a subject in need thereof a solid pharmaceutical composition biopterin derivatives.
1. A method of treating a disease in a subject, comprising the step of administering to a subject in need thereof a solid pharmaceutical composition comprising
a) a compound having the formula (I):
and/or a compound having the formula (II):
and
b) two different sodium phosphate salts, wherein the two different sodium phosphate salts are NaH 2 PO 4 .2H 2 O and Na 2 HPO 4 .2H 2 O, and wherein the quantity of the NaH 2 PO 4 .2H 2 O and Na 2 HPO 4 .2H 2 O present in the composition is chosen such that the molar ratio of both NaH 2 PO 4 .2H 2 O and Na 2 HPO 4 .2H 2 O to compound (I) or compound (II) ranges from 0.02 to 0.5, wherein the disease is selected from the group consisting of traumatic brain injury, non-traumatic brain injury, elevated cranial pressure, and secondary brain injury.
2. The method of claim 1 , wherein the compound (I) and/or the compound (II) are present as the free base.
3. The method of claim 1 , wherein the pharmaceutical composition comprises an additional pharmaceutical excipient.
4. The method of claim 3 , wherein the additional pharmaceutical excipient is an inorganic salt.
5. The method of claim 4 , wherein the inorganic salt is NaCl.
6. The method of claim 1 , wherein the composition further comprises crystallization water.
7. The method of claim 1 , wherein a unit dosage of the composition contains 650±60 mg of the free base of 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or of 4-Amino-7,8-dihydro-L-biopterin, 140±30 mg of water of crystallization, 70±7 mg Na 2 HPO 4 .2H 2 O, 16.5±2 mg NaH 2 PO 4 .2H 2 O, and 350±30 mg NaCl.
8. The method of claim 1 , wherein the non-traumatic brain injury is stroke or meningitis.
9. The method of claim 1 , wherein the pharmaceutical composition is a lyophilized pharmaceutical composition.
10. The method of claim 9 , comprising reconstituting the lyophilized pharmaceutical composition in a pharmaceutically acceptable fluid to form an injectable solution.
11. The method of claim 9 , wherein the injectable solution is administered to the subject by infusion or injection.
12. The method of claim 1 , wherein the compound having the formula (I) or formula (II) is administered at a maximal daily dose selected from the group consisting of about 10 mg/kg body weight, about 8.5 mg/kg body weight, about 7.5 mg/kg body weight, about 5.0 mg/kg body weight, and about 2.5 mg/kg body weight.
13. The method of claim 1 , wherein the compound (I) is (6R)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin.
14. The method of claim 1 , wherein the compound (I) is (6S)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin.
15. The method of claim 1 , wherein the compound (I) is a diastereomeric mixture that comprises more (6R)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin than (6S)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin.
16. The method of claim 15 , wherein the quantity of the (6R)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin and the (6S)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin is chosen such that the ratio of the amount of (6R)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin to the (6S)-4-Amino-5, 6, 7, 8-tetrahydro-L-biopterin ranges from 1.1:1 to 2:1.
17. The method of claim 1 , wherein the subject is a human.